Strides Arcolab gets US approval for Carboplatin injection

Mumbai, Nov 11 : Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) on Friday announced that it has received US FDA approval for Carboplatin Injection 10 mg/ mL packaged in 50 mg/ mL, 150 mg/ 15 mL, 450 mg/ 45 mL and 600 mg/ 60 mL Multi-dose vials.

According to IMS data June'11, the US market for generic Carboplatin is approximately USD 35 Million.

Carboplatin is part of the Oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly.

Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents, and in secondary treatment of advanced ovarian carcinoma which has recurred after prior chemotherapy.

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables. (IBNS -Posted on / )

More from pharmaceutical-news: